profit from every $100 of sales.
$0$100
Bionano Genomics
$1.04-5.45% today
-35.0% in 1 year
1-year low $1.041-year high $1.85
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bionano Genomics sold, what it kept, and what it did with the cash.
Sales went from $27.8 million in 2022 to $28.5 million in 2025, with -$26.4 million of profit last year.
SalesProfit
Bionano Genomics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bionano Genomics | No profit yet | ||
 Illumina | 37.3× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Bionano Genomics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 28 | 36 | 31 | 29 | |
| 6 | 10 | 0 | 13 | |
| -132 | -137 | -76 | -33 | |
| -121 | -222 | -95 | -16 | |
| -133 | -232 | -112 | -26 | |
| -267.71 | -408.60 | -60.05 | -2.46 | |
| 21.4% | 26.5% | 1.2% | 46.3% | |
| -473.7% | -380.0% | -247.8% | -116.9% | |
| -476.9% | -643.7% | -364.0% | -92.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 308 | 214 | 77 | 74 |
| Cash | 5 | 18 | 9 | 3 |
| Total debt | 12 | 10 | 7 | 7 |
| Total liabilities | 58 | 118 | 41 | 29 |
| 249 | 96 | 35 | 44 | |
| 0 | 1 | 2 | 11 | |
| -39.5% | -175.8% | -204.7% | -40.1% | |
| -53.2% | -241.8% | -316.7% | -59.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -125 | -125 | -69 | -16 | |
| 3 | 2 | 0 | – | |
| -128 | -127 | -69 | -16 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 22 | 15 | 10 | 5 |
Valuation
- –
- –
- –
- 0.2×
- 0.5×
- –
- –
- -112.3%
- -181.4%
- 0.0%
Profitability
- 46.3%
- -116.9%
- -92.6%
- -82.8%
- -64.6%
- -86.8%
- -56.2%
- -35.9%
- -65.8%
- 39.9%
Growth
- +0.8%
- –
- +76.3%
- –
- +84.4%
Financial health
- –
- 0.16
- 9.4%
- -145.0×
- 1.98
- 1.74
- 0.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 952
Bottom 3%of 883
Bottom 17%of 870
What analysts expect
- Average price target
- $46.50
- Range
- $1.00 – $175.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.76 | -0.81 | +6.2% |
| Mar 23, 2026 | -0.03 | -0.81 | +96.3% |
| Nov 13, 2025 | -1.59 | -1.81 | +12.2% |
| Aug 14, 2025 | -1.99 | -2.69 | +26.0% |
| May 14, 2025 | -1.15 | -3.49 | +67.0% |
| Mar 31, 2025 | -57.49 | -6.00 | −858.2% |
| Nov 14, 2024 | -19.16 | -0.21 | −9,023.8% |
| Aug 7, 2024 | -14.37 | -0.42 | −3,321.4% |
News
Bionano reiterates $31M-$33M 2026 revenue guidance while targeting adjusted EBITDA neutrality by end of 2027Seeking Alpha · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
69Pass
Philip Fisher
24No pass
Peter Lynch
29No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
24No pass
Questions about Bionano Genomics
Is Bionano Genomics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bionano Genomics AI analysis
What does Bionano Genomics do?
Bionano Genomics, Inc. provides genome analysis software solutions. It is in Medical - Diagnostics & Research.
Does Bionano Genomics pay a dividend?
No. Bionano Genomics does not pay a dividend at the moment.
Is Bionano Genomics stock halal?
No. Bionano Genomics does not pass our halal screen: its debt is 48% of its market value, at or above the 33% limit. How we check
How has Bionano Genomics stock done over the past year?
Down 35.0% over the past twelve months, to $1.04. It traded between $1.04 and $1.85 and is 43.8% below its high.
Who are Bionano Genomics's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Bionano Genomics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.